Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Alphega Oncology Support Programme upskills pharmacists to offer support to cancer patient

Alphega Pharmacy Oncology Support Programme allows community pharmacists from six European countries to enhance support and guidance they provide to cancer patients.

The programme aims to help upskill pharmacists and their teams to provide more expert advice to patients living with cancer, raising their profile in the community as key healthcare providers.


Enhancing knowledge amongst community pharmacists about cancer treatment and its side effects is vital as cancer cases are set to increase if current trends continue.

The programme covers practical help topics, such as oral care, nutrition advice and skin, hair and nail care among others, helping patients to get more of the support they need because community pharmacists are easily accessible, rather than needing to book a GP or consultant appointment.

With rates of cancer forecast to rise throughout Europe , and cancer patients likely on average to visit hospital less often, community pharmacists are well-placed to look to support cancer patients with managing the side-effects of their treatment.

Furthermore, during treatment cancer patients are likely to see a pharmacist more often than a doctor. This trend is set to increase as more treatment is delivered orally at home, rather than intravenously in a hospital environment.

Mariola Valero, Head of Value Proposition from Alphega Pharmacy said: “Going through cancer is all consuming - physically and mentally – that’s why it’s so important to have someone you can count on easily accessible.”

“The Alphega Pharmacy Oncology Support Programme is designed as a helping hand in times of need. We’re hopeful that the supportive care and expert pharmacist advice that Alphega pharmacists are now better able to offer can help make the difficult journey of treatment a little bit easier for oncology patients and their carers.”

“Our pharmacists are trained to facilitate conversations that encourage patients and caregivers to open up about their needs, offer empathetic support, suggest products and other useful information that can help patients to better manage the side-effects of their treatment – both physical and mental. Finally, when treatment ends, our pharmacists can help patients connect with strategies that enable them to return to 'normality' sooner.”

The Alphega Oncology Support Programme is available exclusively to Alphega Pharmacy members. So far, the programme has been available to just over 2,180 pharmacists and Alphega is now planning a series of additional training resources which will focus on prevention and early detection of cancer. Access to the training, and more information about it, is available to Alphega members through their dedicated Alphega consultant.

More For You

NHS app to boost clinical trials

The focus is on encouraging people from underrepresented groups, including minorities from African and Asian heritage, to sign up for clinical trials.

iStock

Government to use NHS app to boost clinical trials

The government’s 10-Year Health Plan is expected to provide a fillip to clinical trials, and it plans to make use of the NHS App to encourage people to sign up as participants.

People will be able to sign up for the NIHR Be Part of Research service (bepartofresearch.uk) on the NHS App for the trials best suited to their interests and needs.

Keep ReadingShow less
US pharma bets big on China to snap up potential blockbuster drugs

Through June, US drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies

US pharma bets big on China to snap up potential blockbuster drugs

US drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments.

Through June, US drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies. That compares with just two such deals in the year-earlier period, according to data from GlobalData provided exclusively to Reuters.

Keep ReadingShow less
Alliance Healthcare team raises thousands with charity bike ride to Paris

The Alliance Healthcare team

Alliance Healthcare team raises thousands with charity bike ride to Paris

Eight Alliance Healthcare team members raised over £55,000 for Theodora Children’s Charity by cycling from Surrey to Paris.

From June 13th-15th, the team took on the gruelling 300 mile cross-border Tour D’Alliance 2025 challenge and raised vital funds to support children who may be living with serious health challenges through Theodora Children’s Charity’s Giggle Doctor programme.

Keep ReadingShow less
Over four million flu vaccines across England in the 2024/25 winter flu season.

Over four million flu vaccines across England in the 2024/25 winter flu season.

CCA release

Community pharmacy administered over four million flu vaccines

Community pharmacy administered over four million flu vaccines across England in the 2024/25 winter flu season, the highest outside of the pandemic, according to the Company Chemists’ Association.

This is nearly 10 per cent higher than the number of flu vaccines administered in 2023/24.

Keep ReadingShow less
Chemotherapy-free leukaemia treatment

The trial found that a combination of two cancer drugs, ibrutinib and venetoclax, could perform better than chemotherapy among patients with chronic lymphocytic leukaemia.

iStock

Chemotherapy-free leukaemia treatment shows promise during trial

In a breakthrough in leukaemia research, scientists in the UK have tested a chemotherapy-free approach, involving a combination of targeted drugs, which may offer better outcomes.

The new treatment could radically change the way chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in adults, is treated.

Keep ReadingShow less